Evaluating the safety and efficacy of novel mRNA vaccines for infectious diseases
Keywords:
mRNA vaccines, infectious diseases, immunogenicity, vaccine safety, SARS-CoV-2, vaccine efficacy, public health, emerging pathogensAbstract
In recent years, the advent of messenger RNA (mRNA) vaccine technology has revolutionized the landscape of infectious disease prevention. Unlike traditional vaccines, mRNA vaccines leverage a synthetic strand of mRNA encoding specific antigens, which, upon delivery into the host cells, triggers an immune response without introducing live or attenuated pathogens. This study evaluates the safety and efficacy of novel mRNA vaccines designed for a range of infectious diseases, with a particular focus on SARS-CoV-2, influenza, and emerging zoonotic viruses. The research employs a multi-phase methodology comprising preclinical and clinical trials. Preclinical studies assess the immunogenicity and safety profile in animal models, highlighting mRNA stability, delivery efficiency, and immunotoxicity. The clinical trials, spanning phases I through III, involve diverse populations, including pediatric, adult, and immunocompromised groups. Key endpoints include antibody titers, cellular immune responses, and the incidence of adverse events. Preliminary findings demonstrate a favorable safety profile, with mild to moderate reactogenicity reported in most cases. The efficacy, measured by neutralizing antibody levels and real-world protection against infections, exceeds 90% in several candidate vaccines. Additionally, the modular design of mRNA vaccines facilitates rapid adaptation to emerging pathogens, offering a significant advantage in outbreak scenarios. Despite promising results, challenges persist, such as cold-chain logistics, long-term durability of immunity, and addressing vaccine hesitancy. This research underscores the transformative potential of mRNA vaccines in combating infectious diseases while emphasizing the need for continuous monitoring and innovation to address limitations.
Downloads
Metrics
References
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery. 2018 Apr;17(4):261-79.
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nature reviews Drug discovery. 2014 Oct;13(10):759-80.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine. 2020 Dec 31;383(27):2603-15. https://doi.org/10.1056/NEJMoa2034577
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England journal of medicine. 2021 Feb 4;384(5):403-16. https://doi.org/10.1056/NEJMoa203538
Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct;586(7830):516-27. https://doi.org/10.1038/s41586-020-2798-3
nderson EJ, Rouphael NG, Widge AT, et al. Initial report of 2019-nCoV mRNA vaccine safety and immunogenicity in adults. The New England Journal of Medicine. 2020;383(20):1941-1950.
Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021. Jama. 2021 Mar 16;325(11):1101-2. https://doi.org/10.1001/jama.2021.1967
Gargano JW, Wallace M, Hadler SC, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination. JAMA. 2021;326(4):331-339.
Maruggi G, Zhang C, Li J, Nair D. mRNA vaccines: state of the art. Frontiers in Immunology. 2019;10: 2961.
Reichmuth AM, Grimm J, Schlee D, et al. Lipid nanoparticles for mRNA delivery. Advanced Drug Delivery Reviews. 2016; 106:135-146.
Dolgin E. How COVID-19 mRNA vaccines changed the landscape of vaccine development. Nature Reviews Drug Discovery. 2021;20(8):613-614.
Mooraki N, Batmany Y, Zoriehzahra SJ, Kakoolaki S. Evaluating the effect of using turmeric (Curcuma longa) on growth performance and hematological parameters of the ornamental fish, Green Terror (Andinocara rivulatus). International Journal of Aquatic Research and Environmental Studies. 2021 May 10;1(1):49-59
Chakma KS, Chowdhury MS. CSA Implementation Using Novel Methodology: RTL Development. Journal of VLSI circuits and systems. 2023;5(02):22-8. https://doi.org/10.31838/jvcs/05.02.04
Azizova F, Polvanova M, Mamatov A, Siddikova S, Khasanova N, Normamatova P, Karshiev A, Zokirov K. Evaluating the impact of community-based fisheries education program on local communities' attitudes towards sustainable fishing practices. International Journal of Aquatic Research and Environmental Studies. 2024;4(S1):71-76. https://doi.org/10.70102/IJARES/V4S1/12
Soh H, Keljovic N. Development of Highly Reconfigurable Antennas for Control of Operating Frequency, Polarization, and Radiation Characteristics for 5g and 6g Systems. National Journal of Antennas and Propagation. 2024 Aug 16;6(1):31-9. https://doi.org/10.31838/NJAP/06.01.05
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.